- Home
- DSM vs RCEL Comparison
DSM vs RCEL Comparison
Compare DSM & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSM
- RCEL
- Stock Information
- Founded
- DSM 1989
- RCEL 2020
- Country
- DSM United States
- RCEL United States
- Employees
- DSM N/A
- RCEL N/A
- Industry
- DSM Investment Managers
- RCEL Medical/Dental Instruments
- Sector
- DSM Finance
- RCEL Health Care
- Exchange
- DSM Nasdaq
- RCEL Nasdaq
- Market Cap
- DSM 301.0M
- RCEL 308.6M
- IPO Year
- DSM N/A
- RCEL N/A
- Fundamental
- Price
- DSM $5.86
- RCEL $9.02
- Analyst Decision
- DSM
- RCEL Buy
- Analyst Count
- DSM 0
- RCEL 5
- Target Price
- DSM N/A
- RCEL $18.00
- AVG Volume (30 Days)
- DSM 161.7K
- RCEL 243.4K
- Earning Date
- DSM 01-01-0001
- RCEL 02-13-2025
- Dividend Yield
- DSM 3.97%
- RCEL N/A
- EPS Growth
- DSM N/A
- RCEL N/A
- EPS
- DSM N/A
- RCEL N/A
- Revenue
- DSM N/A
- RCEL $60,040,000.00
- Revenue This Year
- DSM N/A
- RCEL $36.71
- Revenue Next Year
- DSM N/A
- RCEL $54.48
- P/E Ratio
- DSM N/A
- RCEL N/A
- Revenue Growth
- DSM N/A
- RCEL 32.24
- 52 Week Low
- DSM $4.69
- RCEL $7.51
- 52 Week High
- DSM $6.05
- RCEL $18.93
- Technical
- Relative Strength Index (RSI)
- DSM 47.31
- RCEL 36.61
- Support Level
- DSM $5.79
- RCEL $9.09
- Resistance Level
- DSM $5.86
- RCEL $9.71
- Average True Range (ATR)
- DSM 0.05
- RCEL 0.46
- MACD
- DSM 0.01
- RCEL 0.07
- Stochastic Oscillator
- DSM 70.53
- RCEL 38.24
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.